Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvectis Pharma, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage oncology drug developer with common stock registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and annual financial results, corporate updates, and exhibit press releases describing development activity for NXP900 and related operating progress.
Proxy materials cover annual meeting matters, director elections, auditor ratification, board composition, and stockholder voting procedures. Other material-event filings record governance changes such as director appointments, while cover-page disclosures identify Nuvectis as an emerging growth company and list its common stock trading on the Nasdaq Capital Market under NVCT.
Nuvectis Pharma, Inc. (NVCT) has filed a Form S-3 shelf registration to offer up to $200,000,000 of common stock, preferred stock, warrants, debt securities and units from time to time. The filing uses Rule 415(a)(6) to carry forward approximately $34,821,188 of unsold securities from a prior S-3 declared effective on February 20, 2026, along with the previously paid filing fee.
Within this shelf, Nuvectis has established an at-the-market equity program with Jefferies LLC to sell up to $75,000,000 of common stock on the Nasdaq Capital Market under the symbol NVCT, for up to a 3.0% sales commission. As of August 20, 2026, the company had 32,644,066 shares outstanding and illustrates potential issuance of about 3.2 million ATM shares at a reference price of $23.35. Nuvectis remains an emerging growth and smaller reporting company and highlights an oncology pipeline including NXP100, NXP200 and NXP900.
Nuvectis Pharma, Inc. (NVCT) established a new “at the market” equity offering program by entering into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026. Under this arrangement, Nuvectis may sell shares of its common stock from time to time through Jefferies as sales agent, in transactions deemed an “at the market offering” under Rule 415(a)(4). The program is supported by a new Form S-3 shelf registration statement registering $200 million in securities, for which a prospectus supplement is expected to be filed on August 21, 2026.
Jefferies will use commercially reasonable efforts to place shares but is not obligated to sell any specific amount, and there is no escrow or similar arrangement for proceeds. Nuvectis will pay Jefferies up to 3.0% of the gross proceeds from any shares sold and reimburse certain costs, while providing customary indemnification. On July 20, 2026, Nuvectis terminated its prior at-the-market offering program and related prospectus supplement; no further sales will occur under that prior program.
Nuvectis Pharma, Inc. has a new large shareholder group led by Soleus Capital entities, which collectively report beneficial ownership of 1,648,024 shares of Nuvectis common stock. This represents 5.1% of the outstanding shares, calculated using 32,581,533 shares outstanding as of July 31, 2026.
The holdings are primarily split between Soleus Private Equity Fund III, L.P. with 150,000 shares (0.5%) and Soleus Capital Master Fund, L.P. with 1,498,024 shares (4.6%). All reporting persons state they have shared voting and dispositive power over their respective positions and no sole power, and each expressly disclaims beneficial ownership beyond what is required for Section 13(d) reporting.
Carson Michael J. reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma, Inc. granted Vice President, Finance Michael J. Carson 30,000 shares of restricted common stock on August 3, 2026. These shares will fully vest on August 3, 2027, subject to his continued service. Following this award, he directly holds 230,118 shares of common stock, including restricted shares.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, reported a net loss of $7.0 million for the quarter and $13.1 million for the six months ended June 30, 2026, with no product revenue. Research and development spending rose to $4.7 million in the quarter and $8.8 million year-to-date, driven mainly by clinical and manufacturing costs, while general and administrative expenses declined modestly.
Cash and cash equivalents were $22.2 million on June 30, 2026. In July 2026 the company completed a public equity offering of 5,750,000 shares at $20.00, generating $115.0 million in gross and approximately $106.3 million in net proceeds; management believes this, together with existing cash, will fund planned operations for at least 12 months. Shares outstanding increased from 26.7 million on June 30 to about 32.6 million on July 31, 2026.
In June 2026 Nuvectis licensed global (ex-China and certain territories) rights to NXP100, an oral Factor B inhibitor for complement-related diseases, and NXP200, a brain-penetrant paradox breaker BRAF inhibitor, from Haisco. The agreement became effective upon the July offering and included a $20.0 million upfront payment and potential milestones of up to approximately $1.4 billion, plus tiered royalties, expanding the pipeline alongside existing oncology candidates NXP900 and NXP800.
Nuvectis Pharma, a clinical-stage biopharmaceutical company focused on complement-mediated diseases and oncology, in-licensed new lead candidate ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, and NXP200, an oral brain-penetrant BRAF inhibitor. Ciprocopan recently received its first marketing approval in China for treating paroxysmal nocturnal hemoglobinuria patients not previously treated with complement inhibitors through partner Haisco, representing the first global approval of a once-daily oral Complement Factor B inhibitor. In July 2026, the company completed a $115 million follow-on offering to provide resources for advancing NXP100 and its oncology portfolio.
For the quarter ended June 30 2026, cash and cash equivalents were $22.2 million. Net loss was $7.0 million compared with $6.3 million a year earlier, driven by research and development expenses of $4.7 million and general and administrative expenses of $2.5 million. Basic and diluted net loss per share was $0.30, based on 23,475,989 weighted-average common shares outstanding.
Nuvectis Pharma, Inc. disclosed that Emerald Hill Ventures SARL SPF, which is beneficially owned by 10% owner Charles Mosseri Marlio, executed an open-market purchase of 50,000 shares of common stock at a weighted average price of $18.32 per share. After these transactions, Emerald Hill Ventures SARL SPF holds 3,186,576 shares indirectly, while Marlio also directly owns 109,321 shares of Nuvectis Pharma common stock.
Nuvectis Pharma Chairman and CEO Ron Bentsur bought 12,500 shares of common stock at $20.00 per share in an open-market purchase tied to a public offering announced on June 29, 2026, for a total of $250,000.
After this transaction, he directly owns 3,688,424 shares of Nuvectis Pharma common stock, including shares of restricted common stock.
Nuvectis Pharma, Inc. entered into an underwriting agreement for a firm commitment public offering of 5,000,000 shares of common stock at $20.00 per share, for expected gross proceeds of $100 million. Underwriters also have a 30‑day option to buy up to 750,000 additional shares.
The company expects net proceeds of about $93 million, or approximately $107 million if the underwriters fully exercise the option, after discounts and expenses. The offering is made under Nuvectis’ effective Form S‑3 shelf registration and is expected to close on or about July 1, 2026, subject to customary conditions.
Nuvectis plans to use the net proceeds to advance its pipeline programs NXP100, NXP200, and NXP900, hire additional personnel, fund capital expenditures, cover public company operating costs, and for other general corporate purposes.